This effect of the microbiome regulating the response to ICI therapy was further demonstrated in a phase II single-arm trial, where FMT partially reversed checkpoint inhibitor resistance in PD-1 refractory melanoma [142]. The gene discussed is PDCD1; the disease is melanoma.